FDA partner Julie Tibbets highlights the growing need for companies, showcasing innovative and marketed drug products at large medical meetings, to beware of the U.S. Food and Drug Administration’s Office of Prescription Drug Promotion increased efforts targeting and enforcing exhibit booth content in recent years.
Read the full article.